Q3 2025 Earnings Call Transcript November 10, 2025 FibroGen, Inc. beats earnings expectations. Reported EPS is $-1.61, ...
Cassava Sciences, Inc. (NASDAQ: SAVA, "Cassava", the "Company"), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders such as ...
COM701 Phase 1 data presented at ESMO 2025 characterized patients who derived clinical benefit and informed the design of the ongoing MAIA-ovarian ...
Extendicare Inc. ("Extendicare" or the "Company") (TSX: EXE) today reported results for the three and nine months ended September 30, 2025. Third Quarter ...
Operator: Ladies and gentlemen, thank you for joining us today. And third quarter 2025 results conference call. At this time, ...
Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence ...
Helping students to develop math fluency takes more than just flash cards. It requires teaching them how to think about ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback